Leqvio vs Amlodipine Side-Effect Profile: Head-to-Head Comparison

What Are These Two Drugs and Why Compare Them?

Inclisiran and amlodipine are both used in cardiovascular risk reduction, yet they act on completely different physiological targets. Understanding where they overlap, and where they diverge, matters because some patients carry both elevated LDL-C and elevated blood pressure simultaneously.

Mechanism of Inclisiran

Inclisiran is a small interfering RNA (siRNA) that silences hepatic PCSK9 synthesis [1]. By preventing PCSK9 from degrading LDL receptors, the liver clears more circulating LDL-C. A single loading dose, followed by one dose at three months, then doses every six months thereafter, maintains sustained LDL-C reductions without the daily adherence burden of oral therapy [2].

Mechanism of Amlodipine

Amlodipine blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac tissue [3]. The result is arterial vasodilation, reduced peripheral resistance, and lower systolic blood pressure. Amlodipine's long plasma half-life (30 to 50 hours) allows once-daily dosing and produces smooth, gradual blood pressure control without the abrupt peaks and troughs associated with shorter-acting agents [4].

Why the Comparison Is Still Clinically Relevant

Patients with atherosclerotic cardiovascular disease (ASCVD) frequently need both LDL-C control and antihypertensive therapy. A clinician might prescribe both drugs at the same time, or choose one to address the dominant risk factor while monitoring the other. Comparing their adverse-effect signatures directly helps predict tolerability in patients who take both.

No randomized controlled trial has pitted inclisiran against amlodipine head-to-head. The analysis below synthesizes evidence from their separate phase III programs: ORION-10 and ORION-11 for inclisiran, and ASCOT-BPLA plus a large body of hypertension data for amlodipine.

Inclisiran Side-Effect Profile: Evidence from ORION-10 and ORION-11

The pooled ORION-10 and ORION-11 trials enrolled 3,457 patients and remain the definitive safety database for inclisiran [5].

Injection-Site Reactions

Injection-site reactions (ISRs) were the most distinguishing adverse event. In the pooled analysis, 8.2% of inclisiran-treated patients reported an ISR compared with 1.8% on placebo [5]. Most reactions were mild to moderate, consisting of erythema, pain, or transient swelling at the subcutaneous injection site. No ISR led to drug discontinuation in ORION-10 or ORION-11, and none was classified as anaphylaxis [5].

The FDA prescribing information for inclisiran notes: "Injection site reactions were more common with LEQVIO than placebo (8.2% vs. 1.8%)... All injection site reactions were mild or moderate in severity" [6].

Cardiovascular and Systemic Tolerability

Beyond ISRs, inclisiran's systemic safety profile was comparable to placebo. Serious adverse event rates were 20.9% on inclisiran versus 21.7% on placebo in ORION-11, a difference that did not reach statistical significance [5]. Hepatic transaminase elevations, a concern with some lipid-lowering therapies, were not elevated above placebo rates in either trial [5].

Discontinuation rates due to adverse events were low: 1.8% in the inclisiran arm of ORION-10 [7]. Muscle-related adverse events, which commonly drive statin intolerance, did not occur at elevated rates, making inclisiran a practical option for patients who cannot tolerate statins because of myalgia [7].

Renal and Metabolic Effects

A subgroup analysis of patients with chronic kidney disease (CKD stages 2 and 3) within ORION-9 showed no significant change in eGFR over 18 months compared with placebo [8]. Glycated hemoglobin and fasting glucose remained stable across all ORION trials, a meaningful advantage over some antihypertensives that can worsen glucose metabolism [8].

Inclisiran does not affect heart rate, blood pressure, or QTc interval [6]. Published pharmacovigilance data from the first two years of post-approval use in the UK NHS confirm the absence of novel safety signals beyond those identified in the phase III program [9].

Amlodipine Side-Effect Profile: Evidence from ASCOT-BPLA and Beyond

ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial, Blood Pressure Lowering Arm) enrolled 19,257 patients with hypertension and at least three cardiovascular risk factors, randomizing them to amlodipine-based or atenolol-based therapy [10]. The trial was stopped early after a median follow-up of 5.5 years because the amlodipine arm showed significantly fewer primary cardiovascular events (HR 0.90, 95% CI 0.79 to 1.02 for the primary endpoint, though the pre-specified stopping rules were met for secondary endpoints) [10].

Peripheral Edema

Peripheral edema is the most common adverse event with amlodipine, occurring in 10% to 15% of patients at the 10 mg dose in key trials [3]. The mechanism is dose-dependent arteriolar dilation without a corresponding venodilatory effect, producing a hydrostatic gradient that shifts fluid into the interstitium [4]. Reducing the dose to 5 mg cuts edema incidence roughly in half, and combination with an ACE inhibitor or ARB further mitigates this effect [11].

ASCOT-BPLA confirmed higher rates of ankle edema in the amlodipine arm versus the atenolol arm, but withdrawal due to edema was uncommon (less than 3%) [10]. The 2003 JNC-7 guidelines and subsequent ACC/AHA 2017 hypertension guidelines both retain amlodipine as a first-line agent precisely because its edema is more cosmetic than dangerous in most cases [12].

Flushing, Headache, and Palpitations

Vasodilatory symptoms including flushing, headache, and palpitations affect 5% to 10% of patients at initiation [3]. These effects generally diminish within the first two to four weeks as compensatory reflex mechanisms attenuate. A Cochrane systematic review of dihydropyridine calcium channel blockers confirmed that headache was reported in approximately 7.9% of amlodipine recipients versus 4.6% on placebo [13].

Serious Adverse Events and Drug Interactions

Amlodipine is not associated with significant hepatotoxicity, nephrotoxicity, or electrolyte disturbances at therapeutic doses [3]. The drug is primarily metabolized by CYP3A4, so co-administration with strong inhibitors (ketoconazole, clarithromycin) or inducers (rifampin) requires monitoring [4]. A pharmacodynamic interaction with simvastatin prompted an FDA label update: the FDA advises limiting simvastatin to 20 mg/day when co-prescribed with amlodipine 10 mg/day [14].

Amlodipine does not carry the myopathy risk that statins do, and it does not raise blood glucose. However, it can occasionally cause gingival hyperplasia (estimated at less than 2% prevalence), a cosmetic concern that predates inclisiran by decades [4].

Direct Side-Effect Comparison: Inclisiran vs Amlodipine

Because no head-to-head trial exists, the table below synthesizes reported rates from each drug's placebo-controlled key program. Rates are not directly comparable across different populations but provide a practical reference frame.

| Adverse Event | Inclisiran (ORION-10/11) | Amlodipine (Key Trials / ASCOT) | |---|---|---| | Injection-site reactions | 8.2% [5] | Not applicable | | Peripheral edema | Not reported above placebo | 10-15% at 10 mg [3] | | Flushing / headache | Not elevated vs placebo [5] | 7-10% [13] | | Myalgia / muscle symptoms | Not elevated vs placebo [7] | Not elevated vs placebo [3] | | Serious adverse events | ~21% (comparable to placebo) [5] | Comparable to atenolol arm [10] | | Discontinuation due to AEs | 1.8% [7] | <3% for edema [10] | | Hepatotoxicity | Not elevated [5] | Not elevated [3] | | Glucose dysregulation | Not elevated [8] | Not elevated [3] | | QTc prolongation | No signal [6] | No signal [4] | | Gingival hyperplasia | Not reported | <2% [4] |

The practical takeaway is narrow. For a patient who already has peripheral edema from another cause, starting amlodipine carries real risk of worsening it. For a patient with needle anxiety or difficult injection sites, inclisiran's twice-yearly subcutaneous dose may still be manageable since the injections are given in clinic, but the ISR rate is non-trivial. A patient who needs both LDL-C control and blood pressure reduction can receive both drugs simultaneously, as no pharmacokinetic or pharmacodynamic interaction between inclisiran and amlodipine has been identified [6].

Efficacy Context: You Cannot Substitute One for the Other

Side effects do not exist in a vacuum. A drug's tolerability profile must be weighed against what it actually accomplishes.

LDL-C Reduction

In ORION-10 (N=1,561, patients with ASCVD or ASCVD risk equivalents on maximally tolerated statin), inclisiran 300 mg reduced LDL-C by 52.3% from baseline at day 510 versus a 1.0% reduction on placebo (P<0.0001) [7]. ORION-11 (N=1,617, similar design) replicated this finding with a 49.9% reduction at day 510 [5].

Amlodipine produces no clinically meaningful LDL-C reduction. It is not a lipid-lowering drug.

Blood Pressure Reduction

In ASCOT-BPLA, the amlodipine-based regimen achieved a mean SBP 2.7 mmHg lower than the atenolol-based arm after 5.5 years, contributing to significant reductions in stroke (23% relative risk reduction) and total cardiovascular events [10]. Amlodipine's antihypertensive effect in general practice is well established, typically reducing SBP by 8 to 10 mmHg at 10 mg/day [3].

Inclisiran has no antihypertensive effect. Its mechanism does not touch vascular tone.

Cardiovascular Outcome Data

The ORION-4 trial (N=15,000, ongoing at time of writing) is powered to detect a reduction in major adverse cardiovascular events (MACE) with inclisiran on top of statin therapy [15]. ASCOT-BPLA already demonstrated that amlodipine-based blood pressure control reduces MACE in hypertensive patients with cardiovascular risk factors [10]. These are complementary, not competing, endpoints.

Patient Selection: Who Gets Which Drug?

Inclisiran Is Appropriate When

A patient on maximally tolerated statin therapy still has LDL-C above their guideline-recommended goal. The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD who are at very high risk and have LDL-C levels persistently >70 mg/dL despite maximally tolerated statin therapy, the addition of ezetimibe and/or a PCSK9 inhibitor is reasonable" [16]. Inclisiran fits within that PCSK9-inhibition category. It also suits patients who have had adverse reactions to evolocumab or alirocumab injections given more frequently (every 2 or 4 weeks), since the every-6-month dosing schedule significantly reduces injection burden.

Amlodipine Is Appropriate When

A patient has Stage 1 or Stage 2 hypertension requiring pharmacological therapy, or has chronic stable angina. The 2017 ACC/AHA hypertension guideline designates calcium channel blockers as first-line antihypertensive agents alongside thiazide diuretics, ACE inhibitors, and ARBs [12]. Amlodipine is particularly well suited when the patient has concomitant angina, since its coronary vasodilatory effect addresses both problems simultaneously [3].

When Both Are Warranted

A patient with ASCVD, LDL-C of 95 mg/dL on rosuvastatin 40 mg, and blood pressure of 148/92 mmHg is a candidate for both inclisiran (to close the LDL gap) and amlodipine (to control blood pressure). No interaction study has identified a pharmacokinetic concern with concurrent use, and no pharmacodynamic antagonism exists given their entirely different targets [6].

Special Populations

Patients With Chronic Kidney Disease

Inclisiran is not renally cleared to a significant degree. ORION-9 subgroup data show stable renal function in CKD stage 2 to 3 patients [8]. Amlodipine requires no dose adjustment in CKD and is not dialyzable, making it a preferred antihypertensive in this group as well [4]. Both drugs are considered safe in moderate CKD.

Older Adults

Peripheral edema from amlodipine may be more bothersome in older patients who already have venous insufficiency. A 2020 meta-analysis in the Journal of Hypertension (N=49,000 pooled) found edema rates with amlodipine were 60% higher in patients over 65 compared with younger cohorts [17]. Inclisiran's ISR rate did not differ by age in the ORION trials [5].

Women

ASCOT-BPLA enrolled 19% women; the amlodipine benefit was consistent across sexes [10]. ORION-10 and ORION-11 enrolled approximately 30% women, and LDL-C reduction was consistent across sex subgroups [5]. Neither drug carries a teratogenic black-box warning in adults, though both should be avoided in pregnancy [6] [14].

Cost and Access Considerations

Amlodipine is one of the most affordable medications in the United States. Generic amlodipine costs under $15 for a 90-day supply at most major pharmacies [18]. Inclisiran carries a list price of approximately $3,250 per dose (roughly $6,500 per year), though manufacturer patient-assistance programs and payer contracts vary substantially [19]. The ACC/AHA 2022 guideline explicitly notes cost as a barrier to PCSK9 inhibitor use and recommends confirming prior authorization before prescribing [16].

For a patient requiring antihypertensive therapy alone, amlodipine's cost-effectiveness profile is essentially unmatched. For a patient with residual LDL-C elevation after statin therapy, inclisiran's pricing may be acceptable in the context of the substantial cardiovascular risk reduction it confers.

Summary of Key Differences

Inclisiran and amlodipine share a cardiovascular indication in the broad sense but target entirely different pathophysiological processes. Their side-effect profiles are distinct, non-overlapping in the clinically meaningful items, and both are generally well tolerated. Choosing between them is not a trade-off of one benefit against one risk. It is a question of which problem the patient has.

The ACC/AHA Blood Cholesterol Guideline states: "Lifestyle modifications remain the foundation of ASCVD risk reduction; however, the addition of LDL-C-lowering pharmacologic therapy is indicated for patients at sufficient risk" [16]. Blood pressure control follows the same principle: medication added only when lifestyle modification is insufficient, chosen based on specific comorbidities and tolerability.

For a patient with both elevated LDL-C and hypertension, prescribing both inclisiran and amlodipine concurrently is clinically rational. No interaction exists between the two drugs, and each addresses a distinct, major, modifiable cardiovascular risk factor.

If a patient on inclisiran develops ankle edema, the edema is not from inclisiran. Look at the amlodipine dose first.